INC. (NASDAQ:INCR) Files An 8-K Entry into a Material Definitive Agreement

INC. (NASDAQ:INCR) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

On December 1, 2020, SunHydrogen, Inc. (the “Company”) entered into a securities purchase agreement (“Purchase Agreement”) with the purchaser set forth on the page thereto (the “Purchaser”) for the purchase and sale of an aggregate of 120,000,000 shares of the Company’s common stock (the “Shares”), and warrants to purchase an aggregate of up to 120,000,000 shares of common stock (“Warrants”), in a registered direct offering at a combined purchase price of $0.075 per Share and Warrant, for an aggregate gross proceeds to the Company of $9,000,000. The Warrants will be exercisable for a period commencing upon issuance and expiring 30 months from issuance, at an exercise price of $0.075 per share.

to an engagement letter (the “Engagement Letter”) dated November 30, 2020 by and between the Company and H.C. Wainwright & Co., LLC (“Wainwright”), the Company engaged Wainwright to act as the Company’s exclusive placement agent in connection with the registered direct offering. to the engagement agreement, the Company agreed to pay Wainwright a cash fee of 7.0% of the gross proceeds the Company receives under the Purchase Agreement. The Company also agreed to pay Wainwright (i) a management fee equal to 1.0% of the gross proceeds raised in the offering; (ii) $85,000 for non-accountable expenses; and (iii) closing costs of $5,000. In addition, the Company agreed to issue to Wainwright (or its designees) placement agent warrants (the “Placement Agent Warrants”) to purchase a number of shares equal to 7.0% of the aggregate number of Shares sold under the Purchase Agreement., or warrants to purchase up to an aggregate of 8,400,000 shares. The Placement Agent Warrants generally will have the same terms as the Warrants, except they will have an exercise price of $0.0938 and the Placement Agent Warrants and the shares of common stock issuable thereunder are not registered under the Securities Act of 1933, as amended.

The gross proceeds from the registered direct offering are expected to be approximately $9.0 million, before deducting fees payable to the placement agent and other estimated offering expenses. The Company intends to use the net proceeds primarily to accelerate the development of its breakthrough nanoparticle hydrogen generation technology, as well as for working capital and general corporate purposes. The registered direct offering is expected to close on or about December 3, 2020, subject to the satisfaction of customary closing conditions.

The Shares and Warrants (and underlying shares) were offered, and will be issued, to the Prospectus Supplement, dated December 1, 2020, to the Prospectus included in the Company’s Registration Statement on Form S-3 (Registration No. 333- 239632) filed with the Securities and Exchange Commission on July 2, 2020 and declared effective on July 8, 2020, and Registration Statement on Form S-3MEF (File No. 333- 251064) filed to Rule 462(b).

Sichenzia Ross Ference LLP, counsel to the Company, has issued an opinion to the Company regarding the validity of the securities to be issued in the offering. A copy of the opinion is filed as Exhibit 5.1 to this Current Report on Form 8-K.

The foregoing summaries of the terms of the Purchase Agreement, Warrants, Placement Agent Warrants, and Engagement Letter described herein are subject to, and qualified in their entirety by, such documents, which are incorporated herein by reference.

Item 1.02 Termination of a Material Definitive Agreement

On September 23, 2020, the Company filed a Current Report on Form 8-K to report it had entered into a purchase agreement dated September 21, 2020 (the “GHS Agreement”) with GHS Investments, LLC (“GHS”). On December 1, 2020, the Company terminated the GHS Agreement. Under the GHS Agreement, the Company had the right to sell, in the Company’s discretion (subject to the terms and conditions of the GHS Agreement), up to an aggregate of $4,000,000 of common stock to GHS. As of December 1, 2020, the Company sold $1,700,000 to the GHS Agreement.

  

Item 3.02 Unregistered Sales of Equity Securities.

The information set forth in Item 1.01 is incorporated by reference into this Item 3.02. In connection with the sale of the Placement Agent Warrant, the Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, for transactions not involving a public offering.

Item 8.01 Other Events.

On December 1, 2020, the Company issued a press release regarding the registered direct offering. A copy of the press release is attached as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

5.1 Opinion of Sichenzia Ross Ference LLP
10.1 Form of Securities Purchase Agreement
10.2 Form of Warrant
10.3 Form of Placement Agent Warrant
10.4 Engagement Letter.
99.1 Press release

 


SUNHYDROGEN, INC. Exhibit
EX-5.1 2 ea130906ex5-1_sunhydro.htm OPINION OF SICHENZIA ROSS FERENCE LLP Exhibit 5.1       December 3,…
To view the full exhibit click here

Story continues below

About INC. (NASDAQ:INCR)

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.

An ad to help with our costs